Response Biomedical
This article was originally published in The Gray Sheet
Executive Summary
Rapid, on-site anthrax detection system based on the firm's RAMP technology is launched May 29. Intended for use by emergency responders, the environmental test can distinguish "between a hoax and a potentially infectious dose" in under 15 minutes, the firm claims. Vancouver-based Response hopes to place several hundred of the $10,000 systems by year-end, estimating a $500 mil. U.S. anthrax detection market within two years. The firm is in the process of signing co-marketing and distribution agreements. Separately, Response plans 510(k) submissions for CK-MB and troponin 1 analyte cardiac marker tests by the end of 2002. The RAMP reader was cleared in January for general clinical use along with a myoglobin cardiac marker test...